Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients

4070 Background: Docetaxel/irinotecan combination demonstrates synergy in preclinical models and has activity in a range of solid tumors. Irinotecan and taxanes have recognized activity in esophage...